160 related articles for article (PubMed ID: 38195651)
21. The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo.
Liu M; Wang X; Li H; Xu L; Jing L; Jiang P; Liu B; Li Y
Thorac Cancer; 2019 Oct; 10(10):1868-1878. PubMed ID: 31486270
[TBL] [Abstract][Full Text] [Related]
22. Cancer stem cell-like cells-derived exosomal CDKN2B-AS1 stabilizes CDKN2B to promote the growth and metastasis of thyroid cancer via TGF-β1/Smad2/3 signaling.
Wu Q; He Y; Liu X; Luo F; Jiang Y; Xiang M; Zhao R
Exp Cell Res; 2022 Oct; 419(1):113268. PubMed ID: 35750242
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model.
Guo W; Zhang Y; Chen T; Wang Y; Xue J; Zhang Y; Xiao W; Mo X; Lu Y
J Cancer Res Clin Oncol; 2011 Jan; 137(1):65-72. PubMed ID: 20336315
[TBL] [Abstract][Full Text] [Related]
24. Effect of pyruvate kinase M2-regulating aerobic glycolysis on chemotherapy resistance of estrogen receptor-positive breast cancer.
Qian Y; Bi L; Yang Y; Wang D
Anticancer Drugs; 2018 Aug; 29(7):616-627. PubMed ID: 29782350
[TBL] [Abstract][Full Text] [Related]
25. Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt/β-catenin pathway.
Lv J; Chen FK; Liu C; Liu PJ; Feng ZP; Jia L; Yang ZX; Hou F; Deng ZY
Life Sci; 2020 Sep; 256():117925. PubMed ID: 32522570
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Proliferation, Migration, and Invasion by Knockdown of Pyruvate Kinase-M2 (PKM2) in Ovarian Cancer SKOV3 and OVCAR3 Cells.
Miao Y; Lu M; Yan Q; Li S; Feng Y
Oncol Res; 2016 Oct; 24(6):463-475. PubMed ID: 28281967
[TBL] [Abstract][Full Text] [Related]
27. PKM2 regulates angiogenesis of VR-EPCs through modulating glycolysis, mitochondrial fission, and fusion.
Ren R; Guo J; Shi J; Tian Y; Li M; Kang H
J Cell Physiol; 2020 Sep; 235(9):6204-6217. PubMed ID: 32017072
[TBL] [Abstract][Full Text] [Related]
28. Apatinib Inhibits Stem Properties and Malignant Biological Behaviors of Breast Cancer Stem Cells by Blocking Wnt/β-catenin Signal Pathway through Downregulating LncRNA ROR.
Jiang B; Zhu H; Tang L; Gao T; Zhou Y; Gong F; Tan Y; Xie L; Wu X; Li Y
Anticancer Agents Med Chem; 2022; 22(9):1723-1734. PubMed ID: 33845750
[TBL] [Abstract][Full Text] [Related]
29. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
[TBL] [Abstract][Full Text] [Related]
30. Pyruvate kinase M2 in blood circulation facilitates tumor growth by promoting angiogenesis.
Li L; Zhang Y; Qiao J; Yang JJ; Liu ZR
J Biol Chem; 2014 Sep; 289(37):25812-21. PubMed ID: 25070887
[TBL] [Abstract][Full Text] [Related]
31. Paeonol inhibits the malignancy of Apatinib-resistant gastric cancer cells via LINC00665/miR-665/MAPK1 axis.
Li M; Cai O; Yu Y; Tan S
Phytomedicine; 2022 Feb; 96():153903. PubMed ID: 35026514
[TBL] [Abstract][Full Text] [Related]
32. ARHGAP24 represses β-catenin transactivation-induced invasiveness in hepatocellular carcinoma mainly by acting as a GTPase-independent scaffold.
Yang W; Wang B; Yu Q; Liu T; Li T; Tian T; Jin A; Ding L; Chen W; Wang H; Xian J; Pan B; Zhou J; Fan J; Yang X; Guo W
Theranostics; 2022; 12(14):6189-6206. PubMed ID: 36168627
[No Abstract] [Full Text] [Related]
33. Pyruvate kinase M2 inhibits the progression of bladder cancer by targeting MAKP pathway.
Zhu Q; Hong B; Zhang L; Wang J
J Cancer Res Ther; 2018 Sep; 14(Supplement):S616-S621. PubMed ID: 30249877
[TBL] [Abstract][Full Text] [Related]
34. Pyruvate kinase M2 activation protects against the proliferation and migration of pulmonary artery smooth muscle cells.
Zhang A; Yu F; Yu W; Ye P; Liu P; Gu Y; Chen S; Zhang H
Cell Tissue Res; 2020 Dec; 382(3):585-598. PubMed ID: 32719938
[TBL] [Abstract][Full Text] [Related]
35. Subcellular compartmentalization of PKM2 identifies anti-PKM2 therapy response in vitro and in vivo mouse model of human non-small-cell lung cancer.
Suzuki A; Puri S; Leland P; Puri A; Moudgil T; Fox BA; Puri RK; Joshi BH
PLoS One; 2019; 14(5):e0217131. PubMed ID: 31120964
[TBL] [Abstract][Full Text] [Related]
36. Apatinib Inhibits Angiogenesis in Intrahepatic Cholangiocarcinoma by Regulating the Vascular Endothelial Growth Factor Receptor-2/Signal Transducer and Activator of Transcription Factor 3/Hypoxia Inducible Factor 1 Subunit Alpha Signaling Axis.
Huang MP; Gu SZ; Huang B; Li GW; Xiong ZP; Tang T; Zeng SN
Pharmacology; 2021; 106(9-10):509-519. PubMed ID: 34412054
[TBL] [Abstract][Full Text] [Related]
37. Ropivacaine inhibits proliferation, invasion, migration and promotes apoptosis of papillary thyroid cancer cells via regulating ITGA2 expression.
Qin A; Liu Q; Wang J
Drug Dev Res; 2020 Sep; 81(6):700-707. PubMed ID: 32314406
[TBL] [Abstract][Full Text] [Related]
38. Oviductus ranae protein hydrolysate (ORPH) inhibits the growth, metastasis and glycolysis of HCC by targeting miR-491-5p/PKM2 axis.
Xu Q; Dou C; Liu X; Yang L; Ni C; Wang J; Guo Y; Yang W; Tong X; Huang D
Biomed Pharmacother; 2018 Nov; 107():1692-1704. PubMed ID: 30257387
[TBL] [Abstract][Full Text] [Related]
39. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer.
Lin Y; Zhai E; Liao B; Xu L; Zhang X; Peng S; He Y; Cai S; Zeng Z; Chen M
Oncotarget; 2017 Feb; 8(7):11990-12002. PubMed ID: 28061477
[TBL] [Abstract][Full Text] [Related]
40. Combining transcatheter arterial embolization with iodized oil containing Apatinib inhibits HCC growth and metastasis.
Zhou C; Yao Q; Zhang H; Guo X; Liu J; Shi Q; Huang S; Xiong B
Sci Rep; 2020 Feb; 10(1):2964. PubMed ID: 32076049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
